Kyntra Bio

Kyntra Bio EBIT Margin

The EBIT Margin (Operating Margin) of Kyntra Bio (KYNB) as of Oct 20, 2026 is -814.88 %. In the previous year, EBIT Margin (Operating Margin) was -489.92 % — a change of 66.33% (lower).

EBIT Margin

-814.88 %

YoY

66.33%

Last updated:

EBIT Margin (Operating Margin) of Kyntra Bio is 2025 -814.88 % . EBIT Margin (Operating Margin) of Kyntra Bio was 2024 -489.92 % . It decreases by 66.33% lower compared to the previous year.

Kyntra Bio's operating (EBIT) margin stands at -814.9%, down from -148.1% several years earlier.

The Kyntra Bio EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-40.71 USD
Jan 1, 2019
-34.81 USD
Jan 1, 2020
-108.83 USD
Jan 1, 2021
-148.12 USD
Jan 1, 2022
-213.90 USD
Jan 1, 2023
-689.53 USD
Jan 1, 2024
-489.92 USD
Jan 1, 2025
-814.88 USD
The Kyntra Bio EBIT Margin history
YEAREBIT MarginYoY
-814.88 %+66.33%
-489.92 %-28.95%
-689.53 %+222.37%
-213.90 %+44.41%
-148.12 %+36.10%
-108.83 %+212.63%
-34.81 %-14.49%
-40.71 %-58.28%
-97.57 %+226.55%
-29.88 %-30.40%
-42.93 %+17.90%
-36.41 %+46,699.84%
-0.08 %-81.16%
-0.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kyntra Bio Stock analysis

What does Kyntra Bio do? Kyntra Bio Inc is a biopharmaceutical company based in San Francisco, United States, operating within the health care sector. Listed on November 14, 2014, the firm engages in the discovery, development, and commercialization of novel therapeutics. It leverages expertise in hypoxia-inducible factor and connective tissue growth factor biology to create innovative medicines. The company is developing roxadustat for anemia associated with chronic kidney disease, myelodysplastic syndromes, and chemotherapy-induced anemia. Additionally, it is researching pamrevlumab for conditions such as idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. The organization currently employs 34 people in its operations. Kyntra Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kyntra Bio stock

EBIT Margin (Operating Margin) of Kyntra Bio is -814.88 % in 2025.

EBIT Margin (Operating Margin) of Kyntra Bio changed from -489.92 % to -814.88 %, representing a 66.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Kyntra Bio since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Kyntra Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Kyntra Bio

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Kyntra Bio